Video

Q&A With Paul Hudson of AstraZeneca US: Proving Value in Diabetes Care

Author(s):

As the healthcare landscape has changed in recent years everyone from patients to doctors to pharmaceutical companies have had to change along with it.

As the healthcare landscape has changed in recent years everyone from patients to doctors to pharmaceutical companies have had to change along with it.

Paul Hudson, President of AstraZeneca US discussed how the changes have affected the industry during the American Diabetes Association's 75th Annual Scientific Sessions in Boston. Hudson said pharmaceutical companies now need to work closer with providers to ensure they are getting the best product possible to help their patients "for the most sensible use of the healthcare dollar in the United States."

Related Videos
Caroline Piatek, MD: High HCRU, Patient Concerns Highlight Great Unmet Need in wAIHA
Steven W. Pipe, MD: Supporting Gene Therapy Implementation for Hemophilia
Corinna L. Schultz, MD: Improving Sickle Cell Trait Documentation in Infancy
Sibgha Zaheer, MD: Determining Washout Period With Fitusiran, Emicizumab Transition for Hemophilia
Pavan K. (Tem) Bendapudi, MD: Large-Scale Analyses Elucidate Genetic Risk of Thrombosis
Seema Rani, MD: Examining Sleep Health in Youth With SCD
Daniel Wang: A More Appropriate Ferritin Threshold is Cost-Effective for Iron Deficiency Screening
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
© 2025 MJH Life Sciences

All rights reserved.